Screener
Bausch Health Companies BHC Salix — SG&A
Other segment segments
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by Bausch Health Companies in its filing.
Tagged under the XBRL concept us-gaap:SellingGeneralAndAdministrativeExpense.
The source filing: Bausch Health Companies’s 10-Q, filed April 30, 2026.
- Filed
- Apr 29, 2026, 6:12 PM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0000885590-26-000053
| (in millions) | Three Months Ended March 31, / Salix / 2026 | Three Months Ended March 31, / Salix / 2025 | Three Months Ended March 31, / International / 2026 | Three Months Ended March 31, / International / 2025 | Three Months Ended March 31, / Solta Medical / 2026 | Three Months Ended March 31, / Solta Medical / 2025 | Three Months Ended March 31, / Diversified / 2026 | Three Months Ended March 31, / Diversified / 2025 | Three Months Ended March 31, / Bausch + Lomb / 2026 | Three Months Ended March 31, / Bausch + Lomb / 2025 | Three Months Ended March 31, / Total / 2026 | Total / 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Less: | ||||||||||||
| Cost of goods sold (a) | 47 | 43 | 112 | 102 | 53 | 27 | 27 | 30 | 482 | 481 | ||
| Cost of other revenues | — | — | 16 | 17 | — | — | — | — | 1 | 1 | ||
| Selling, general and administrative | 105 | 111 | 63 | 52 | 35 | 28 | 43 | 45 | 439 | 447 | ||
| Research and development | 19 | 17 | 6 | 6 | 8 | 5 | 3 | 3 | 45 | 28 | ||
| Segment profit | $468 | $371 | $88 | $85 | $75 | $53 | $112 | $127 | $277 | $180 | $1,020 | $816 |
| Corporate | (258) | (268) | ||||||||||
| Amortization of intangible assets | (241) | (256) |
Item 1. Condensed Consolidated Financial Statements (unaudited)
FAQ
- What is Bausch Health Companies's salix — SG&A?
- Bausch Health Companies (BHC) reported salix — SG&A of $105M in Q1 2026.
- How has Bausch Health Companies's salix — SG&A changed year-over-year?
- Bausch Health Companies's salix — SG&A decreased by 5.4% year-over-year, from $111M to $105M.
- What is the long-term trend for Bausch Health Companies's salix — SG&A?
- Over 3 years (2022 to 2025), Bausch Health Companies's salix — SG&A has grown at a 3.6% compound annual growth rate (CAGR), from $362M to $402M.
- What does salix — SG&A mean?
- Includes all operating expenses related to the sales, marketing, and administrative support functions dedicated to the Salix segment. This metric tracks the cost of commercializing products, including sales force compensation and promotional activities. Monitoring this helps assess the operational efficiency and cost-to-serve ratio of the segment's product portfolio.
Ask your AI about Bausch Health Companies's salix — sg&a.
Connect your AI assistant and compare segments, right in your chat.
Connect your AI
Claude